One week of extended-release morphine does not significantly reduce the intensity of worst breathlessness<\/p>\n<\/h3>\n
By Elana Gotkine HealthDay Reporter<\/b><\/p>\n
<\/b><\/p>\n
WEDNESDAY, Nov. 30, 2022 (HealthDay News) — Daily low-dose extended release morphine does not significantly reduce the intensity of worst breathlessness among people with chronic obstructive pulmonary disease (COPD) and severe chronic breathlessness, according to a study published in the Nov. 22\/29 issue of the Journal of the American Medical Association<\/em>.<\/p>\n Magnus Ekstr \u00b6m, M.D., Ph.D., from Lund University in Sweden, and colleagues conducted a double-blind trial involving people with COPD and chronic breathlessness at 20 centers in Australia. A total of 160 participants were randomly assigned to 8 mg\/day or 16 mg\/day of oral extended-release morphine or placebo during week 1 in a 1:1:1 ratio. Participants were randomly assigned to 8 mg\/day extended-release morphine, added to the previous dose, or placebo in a 1:1 ratio at the start of weeks 2 and 3. Overall, 138 participants completed treatment at week 1.<\/p>\n The researchers found that the change in the intensity of worst breathlessness at week 1 did not differ significantly between the 8-mg\/day morphine and placebo groups or between the 16-mg\/day morphine and placebo groups. The secondary outcome of change in mean daily step count was not significantly different between the 8-mg\/day and placebo groups, the 16-mg\/day and placebo groups, the 24-mg\/day and placebo groups, or the 32-mg\/day and placebo groups at week 3.<\/p>\n “These findings do not support the use of these doses of extended-release morphine to relieve breathlessness,” the authors write.<\/p>\n Abstract\/Full Text (subscription or payment may be required)<\/a><\/p>\n Editorial (subscription or payment may be required)<\/a><\/p>\n <\/i><\/p>\n